

Results	Cohort 1 mFOLFOX6 + Bevacizumab	Cohort 2 mFOLFOX6 + Bevacizumab	Cohort 1+2 mFOLFOX6 + Bevacizumab
Median PFS (months)	5.2 (n=26)	8.2 (n=15)	7.2 (n=41)
Median OS (months)	10.8 (n=22)	14.3 (n=9)	12.7 (n=31)
Overall RR (%)	42.3	66.7	51.2
Disease control rate (%)	80.8	93.4	85.3
Stable disease, n (%)	10 (38.5)	4 (26.7)	14 (34.1)
Partial remission, n (%)	10 (38.5)	10 (66.7)	20 (48.8)
Complete remission, n (%)	1 (3.8)	0 (0.0)	1 (2.4)
Progressive disease, n (%)	5 (19.2)	1 (6.7)	6 (14.6)

Abbreviations: PFS: progression free survival, OS: overall survival, RR: response rate, mFOLFOX6: fluorouracil, folinic acid and oxaliplatin